Helix Management, Inc. is a healthcare investment advisory firm. Helix was founded to focus on life sciences companies – where we have the experience, knowledge and network to identify compelling investments across the spectrum of small private companies to large pharmaceutical firms. Helix backs experienced management teams executing promising business plans to discover, develop and commercialize novel therapeutics, medical devices and diagnostics.

Helix develops and manages healthcare investment portfolios for institutional investors. Helix seeks to invest in undervalued life sciences companies by purchasing securities in the open market as well as through directly negotiated transactions. Helix’s capabilities include:

• Proprietary network of healthcare industry executives and clinical consultants
  
• Translating technical scientific advice into actionable investment ideas
  
• Primary research coverage of product companies
  
• Structuring investment strategies with enhanced risk/reward characteristics

Helix also advises institutional investors on negotiated transactions, including direct investments in private and public life sciences companies as well as pharmaceutical and biotechnology product royalty and revenue streams, royalty-related debt and equity vehicles. Helix has advised clients on proposed royalty-related transactions with an aggregate acquisition value in excess of $1 billion. Helix has advised institutional investors, fund of funds, and family offices on their healthcare alternative investment strategies, including investments in healthcare hedge funds and private equity funds.

Copyright © 2003-2021 Helix Management, Inc. All rights reserved.